Karyopharm Therapeutics announced that its Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer failed to meet its primary endpoint of progression-free survival, despite showing a trend favoring the drug. This significant clinical setback led to a sharp decline in the company's stock price, as a key pipeline asset underperformed expectations.
Karyopharm Therapeutics experienced a massive stock price drop after its Phase 3 trial for selinexor in endometrial cancer did not achieve its primary endpoint. This is a critical blow for the company, as the failure of a late-stage clinical trial can significantly impact future revenue potential and investor confidence. While Karyopharm stated this doesn't affect other programs and they will reduce investment in endometrial cancer, prioritizing myelofibrosis and multiple myeloma, the immediate market reaction reflects the loss of a significant growth driver. Traders face a short-term risk of continued downward pressure due to the clinical setback, despite the company's plans to pursue other indications and submit an sNDA for myelofibrosis.